Search

everythinglearnresearchcommunity

for

Search:↓

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Paroxetine relieves pain by increasing allopregnanolone levels.

New cytokine-targeted therapies show promise for treating alopecia areata.

Cepharanthine effectively reduces Herpes Simplex Virus Type 1 by blocking certain cell pathways and promoting cell death.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Certain drugs can cause early hair growth in mice by affecting the nerves.

Scientists created tiny particles loaded with a hair growth drug, minoxidil, that specifically target hair follicles and skin cells to potentially improve hair growth.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Blocking Oncostatin M's role in the JAK-STAT pathway can stimulate hair growth in mice.

A new treatment using gold nanoclusters can safely reduce unwanted hair growth.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Upadacitinib effectively treated severe hair loss in a child.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

Kojyl cinnamate ester derivatives can promote hair growth by increasing adiponectin production in fat tissues.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

Pranlukast and mirabegron may work as new diabetes drugs.

New drug uses show promise but need more research.

The gel improves hair regrowth and reduces irritation in alopecia areata treatment.

Entospletinib effectively prevents eye and skin GVHD in mice.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

Botulinum toxin type A and platelet-rich plasma together boost hair growth by activating specific growth pathways.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.